| abstract |
Methods of using glucagon-like peptide 1 receptor (GLP1R) agonists are generally disclosed herein. In certain aspects, the disclosure provides methods of treating type 2 diabetes that include administering a GLP1R agonist according to certain dosage regimens. In certain other aspects, the disclosure provides methods of treating obesity that include administering a GLP1R agonist according to certain dosage regimens. In certain other aspects, the disclosure provides methods of lowering glycated hemoglobin (for example, lowering HbA1c) that include administering a GLP1R agonist according to certain dosage regimens. Compositions containing GLP1R agonists and their manufacture, for example, for use as a medicament are also disclosed herein. |